Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology

Treatment Pathways: From First-Line to Advanced Therapies

At a Glance

The first-line treatment for Subcorneal Pustular Dermatosis (SPD) is Dapsone, an oral medication that effectively clears skin pustules. Because Dapsone requires strict blood monitoring, second-line treatments like Colchicine, Acitretin, or biologic therapies are used if side effects occur.

Managing Subcorneal Pustular Dermatosis (SPD) is a marathon, not a sprint. Because the condition is chronic and tends to flare up over time, the goal of treatment is to clear the skin during a flare and maintain that clearance with the fewest side effects possible [1][2].

First-Line Treatment: Dapsone

The gold standard and first choice for treating SPD is Dapsone [3]. This medication is highly effective at stopping the accumulation of neutrophils (the white blood cells causing the pustules) in the skin [4].

While Dapsone is effective, it requires careful medical supervision due to two primary safety concerns:

  • Hemolysis: This is the breakdown of red blood cells. It happens to some degree in everyone taking Dapsone, but can be severe in people with a genetic condition called G6PD deficiency [5][6]. Doctors must test for this deficiency before you take your first dose.
  • Methemoglobinemia: This is a condition where your blood can still carry oxygen, but it cannot release it effectively to your body’s tissues [7]. Symptoms can include a blue or gray tint to the skin, lips, or nails, as well as shortness of breath [8]. If you experience a blue/gray tint to your skin or lips and sudden shortness of breath, stop the medication immediately and seek emergency medical care.

Monitoring Your Health on Dapsone

Because of these risks, your doctor will likely require frequent blood tests, especially in the first few months of treatment.

  • Complete Blood Count (CBC): To check for anemia (low red blood cells) and to monitor for agranulocytosis (a dangerous drop in white blood cells) [9]. A severe drop in white blood cells leaves you highly vulnerable to infections, so you must report any signs of infection (like fever or chills) immediately.
  • Liver Function Tests (LFTs): To monitor for rare but serious hepatotoxicity (liver damage) [10][11].
  • G6PD Screening: A one-time test before starting the drug [5].

The Treatment Pathway

If Dapsone is not an option for you—either because of side effects or because it doesn’t clear your skin—doctors have a “ladder” of other treatments to consider:

  1. Second-Line (Non-Biologics):
    • Colchicine: Originally a gout medication, it can help prevent neutrophils from moving into the skin [12].
    • Retinoids (Acitretin): These vitamin-A derivatives help regulate skin cell growth and can be effective [13]. Note: Acitretin is severely teratogenic (causes severe birth defects), requiring strict, long-term pregnancy prevention for female patients of childbearing age.
  2. Advanced/Refractory Options:
    • TNF-alpha Inhibitors: Biologic medications like adalimumab or infliximab have shown success in patients who do not respond to traditional pills [14][15].
    • Topical Options: In milder cases, topical dapsone gel can sometimes be used directly on the spots to avoid the risks of taking a pill [16].

Emerging Research

Modern medicine is exploring new ways to treat “neutrophilic” diseases like SPD. Researchers are looking into JAK inhibitors (such as upadacitinib), which are oral medications that block specific inflammation pathways [17]. While these are not yet the standard for SPD, they represent a growing field of options for patients with difficult-to-treat disease [18].

Always discuss the potential benefits and risks of each “step” on the treatment ladder with your dermatology team to find the plan that fits your specific needs. For more about long-term care and screening, continue to Systemic Health.

Common questions in this guide

What is the first-line treatment for Subcorneal Pustular Dermatosis?
Dapsone is the gold standard and first choice for treating SPD. It is highly effective at stopping the white blood cells that cause pustules from accumulating in the skin.
Why do I need a G6PD blood test before starting Dapsone?
Dapsone can cause a severe breakdown of red blood cells in people with a genetic G6PD deficiency. Your doctor must test for this deficiency before you take your first dose to ensure the medication is safe for you.
What blood tests are required while taking Dapsone?
Your doctor will require frequent Complete Blood Counts (CBC) to check for anemia and dangerous drops in white blood cells. You will also need regular liver function tests to monitor for rare but serious liver damage.
What should I do if my skin turns blue while on Dapsone?
A blue or gray tint to your skin, lips, or nails accompanied by shortness of breath can be a sign of methemoglobinemia. If you experience these symptoms, stop taking the medication immediately and seek emergency medical care.
What are the alternatives if Dapsone does not work for my SPD?
If Dapsone is ineffective or causes severe side effects, your dermatologist may prescribe second-line treatments like Colchicine or oral retinoids. For difficult-to-treat cases, advanced biologic medications like TNF-alpha inhibitors may be an option.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I been tested for G6PD deficiency before starting Dapsone, and why is this test important for my safety?
  2. 2.What specific blood tests (CBC, LFTs) do I need while on Dapsone, and how often should they be performed?
  3. 3.If Dapsone causes side effects or doesn't work, would Colchicine or a TNF-alpha inhibitor (like adalimumab) be a suitable next step for me?
  4. 4.What are the signs of methemoglobinemia I should watch for at home, and when should I seek emergency care?
  5. 5.Is a topical dapsone gel an option for my milder flares to avoid systemic side effects?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Subcorneal pustular dermatosis: Comprehensive review and report of a case presenting during pregnancy

    Bhargava S, Kumar U, Kroumpouzos G

    International journal of women's dermatology 2020; (6(3)):131-136 doi:10.1016/j.ijwd.2020.02.003.

    PMID: 32637535
  2. 2

    Treatment of Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Disease) With Anti-Tumor Necrosis Factor Alpha.

    Guerin C, Beylot-Barry M, Frouin E, et al.

    Cureus 2021; (13(8)):e17147 doi:10.7759/cureus.17147.

    PMID: 34532181
  3. 3

    Subcorneal Pustular Dermatosis: A Review of 30 Years of Progress.

    Watts PJ, Khachemoune A

    American journal of clinical dermatology 2016; (17(6)):653-671 doi:10.1007/s40257-016-0202-8.

    PMID: 27349653
  4. 4

    When Rings Are Not Ringworms: Case Reports and Review of Literature.

    Khalid N, Baig BU, Bhatti H, Rao BK

    Connecticut medicine 2015; (79(2)):77-80.

    PMID: 26244204
  5. 5

    Challenges in Managing a Lepromatous Leprosy Patient Complicated with Melioidosis Infection, Dapsone-Induced Methemoglobinemia, Hemolytic Anemia, and Lepra Reaction.

    Tang ASO, Wong QY, Yeo ST, et al.

    The American journal of case reports 2021; (22()):e931655 doi:10.12659/AJCR.931655.

    PMID: 34038399
  6. 6

    Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model.

    Dziewulska KH, Reisz JA, Hay AM, et al.

    The Journal of pharmacology and experimental therapeutics 2023; (386(3)):323-330 doi:10.1124/jpet.123.001634.

    PMID: 37348965
  7. 7

    Methaemoglobinaemia as an Alternative Diagnosis for Shortness of Breath: A Case Report.

    Thiri T, San SS, Lwin ZT

    Cureus 2025; (17(5)):e83525 doi:10.7759/cureus.83525.

    PMID: 40470439
  8. 8

    Dapsone-induced methemoglobinemia-A case report.

    Kabir H, Lakshmanan R, Gopinath S, Bhonagiri D

    Clinical case reports 2021; (9(5)):e04054 doi:10.1002/ccr3.4054.

    PMID: 34084488
  9. 9

    Anaemia in Dermatitis Herpetiformis: Prevalence and Associated Factors at Diagnosis and One-year Follow-up.

    Alakoski A, Pasternack C, Reunala T, et al.

    Acta dermato-venereologica 2021; (101(4)):adv00443 doi:10.2340/00015555-3795.

    PMID: 33846758
  10. 10

    Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia.

    Ezhilarasan D

    Drug and chemical toxicology 2021; (44(3)):330-333 doi:10.1080/01480545.2019.1679829.

    PMID: 31631707
  11. 11

    Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent.

    Quaresma MV, Bernardes Filho F, Hezel J, et al.

    Anais brasileiros de dermatologia 2015; (90(3 Suppl 1)):51-4.

    PMID: 26312673
  12. 12

    Treatment of Subcorneal Pustular Dermatosis without Dapsone: A Case Report and Review of the Literature.

    Wanberg LJ, Schultz B, Goyal A

    Case reports in dermatological medicine 2024; (2024()):8140483 doi:10.1155/2024/8140483.

    PMID: 38596599
  13. 13

    Subcorneal pustular dermatosis associated with IgG monoclonal gammopathy of undetermined significance.

    Young PA, Bae GH, Konia TH

    Dermatology online journal 2021; (27(4)).

    PMID: 33999577
  14. 14

    Subcorneal pustular dermatosis masquerading as eczematous dermatitis: a case report and mechanistic review.

    Dimitrion P, Espinosa ML, Veenstra J

    BMJ case reports 2025; (18(7)) doi:10.1136/bcr-2025-266247.

    PMID: 40744633
  15. 15

    Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab.

    Chen J, Luo Y, Yu N, et al.

    Clinical, cosmetic and investigational dermatology 2022; (15()):2567-2570 doi:10.2147/CCID.S391594.

    PMID: 36466943
  16. 16

    Successful treatment of recalcitrant subcorneal pustular dermatosis with oral nicotinamide.

    Yamaguchi Y, Oyama N, Koizumi H, et al.

    The Journal of dermatology 2019; (46(11)):e438-e440 doi:10.1111/1346-8138.14980.

    PMID: 31187880
  17. 17

    Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies.

    Lauletta G, Patruno C, Brescia C, et al.

    Antibodies (Basel, Switzerland) 2025; (14(4)) doi:10.3390/antib14040104.

    PMID: 41440493
  18. 18

    Treatment of atopic dermatitis with upadacitinib: adcare single center experience.

    Fomina DS, Mukhina OA, Mikhailova VI, et al.

    Frontiers in medicine 2024; (11()):1385720 doi:10.3389/fmed.2024.1385720.

    PMID: 38695023

This page discusses treatments and side effects for Subcorneal Pustular Dermatosis for educational purposes only. Always consult your dermatologist to determine the safest and most effective medication plan for your specific needs.

Get notified when new evidence is published on Subcorneal pustular dermatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.